Point-of-Care i-STAT Cardiac Troponin I for Assessment of Patients with Symptoms Suggestive of Acute Coronary Syndrome,
Why the study?
Does point-of-care i-STAT cardiac troponin I testing predict 60-day adverse outcomes in patients presenting with symptoms suggestive of acute coronary syndrome?
Population
367 consecutive patients presenting with symptoms suggestive of acute coronary syndrome admitted through the…
Comparison
Point-of-care i-STAT cardiac troponin I assay… vs cTnI concentrations ≤0.04 microg/L
Design
Cohort
Follow-up
60 days
Authors
Discussion
Loading...
Member takes
Implication
May support point-of-care cTnI risk stratification in suspected ACS; leaves open prospective validation before guiding therapy.
Structured PICO
Does point-of-care i-STAT cardiac troponin I testing predict 60-day adverse outcomes in patients presenting with symptoms suggestive of acute coronary syndrome?
P
Population
367 consecutive patients presenting with symptoms suggestive of acute coronary syndrome (ACS) admitted through the emergency department.
I
Intervention
Point-of-care i-STAT cardiac troponin I (cTnI) assay with concentrations >0.04 microg/L (99th percentile reference limit)
C
Comparator
cTnI concentrations ≤0.04 microg/L
O
Outcome
All-cause death (ACD), MI or ACD, MI or cardiac death, and cardiac death at 60 dayshard clinical
Point-of-care i-STAT cTnI testing effectively risk-stratifies patients with suspected ACS for 60-day adverse outcomes including death and MI.
Cite This Study
Apple et al. (2006) studied this question.